Madhu Chhanda Mohanty

Dr. Madhu Chhanda Mohanty

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MMMadhu Chhanda Mohanty
Madhu Chhanda Mohanty
MMManisha Rajan Madkaikar
Manisha Rajan Madkaikar
MDMukesh Desai
Mukesh Desai
PTPrasad Taur
Prasad Taur
UNUma Prajwal Nalavade
Uma Prajwal Nalavade
JDJagadish Mohanrao Deshpande
Jagadish Mohanrao Deshpande
Prolonged excretion of poliovirus can occur in immunodeficient patients who receive oral polio vaccine, which may lead to propagation of highly divergent vaccine-derived polioviruses (VDPVs), posing a concern for global polio eradication. This study aimed to estimate the proportion of primary immunodeficient children with enterovirus infection and to identify the long-term polio/nonpolio enterovirus excreters in a tertiary care unit in Mumbai, India. During September 2014–April 2017, 151 patients received diagnoses of primary immunodeficiency (PID). We isolated 8 enteroviruses (3 polioviruses and 5 nonpolio enteroviruses) in cell culture of 105 fecal samples collected from 42 patients. Only 1 patient with severe combined immunodeficiency was identified as a long-term VDPV3 excreter (for 2 years after identification of infection). Our results show that the risk of enterovirus excretion among children in India with PID is low; however, systematic screening is necessary to identify long-term poliovirus excreters until the use of oral polio vaccine is stopped.

16 September 2021 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
MMMadhu Chhanda Mohanty
Madhu Chhanda Mohanty
PTPrasad D. Taur
Prasad D. Taur
USUnnati Prashant Sawant
Unnati Prashant Sawant
RYReetika Malik Yadav
Reetika Malik Yadav
VPVarsha Potdar
Varsha Potdar

23 July 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
MMMadhu Chhanda Mohanty
Madhu Chhanda Mohanty
MMManisha Ranjan Madkaikar
Manisha Ranjan Madkaikar
MDMukesh Desai
Mukesh Desai
JAJahnavi Aluri
Jahnavi Aluri
SVSwapnil Yashwant Varose
Swapnil Yashwant Varose
JDJagadish Mohanrao Deshpande
Jagadish Mohanrao Deshpande
The emergence of immunodeficiency-associated vaccine-derived polioviruses (iVDPV) from children with primary immunodeficiency disorders poses a threat to the eradication program. Herein, we report a patient with severe combined immunodeficiency (SCID), identified as a prolonged serotype 3 iVDPV (iVDPV3) excreter with 13 VDPV3 isolates and a maximum of 10.33% nucleotide divergence, who abruptly cleared infection after a period of 2 years. Occurrence of an episode of norovirus diarrhea associated with increased activated oligoclonal cytotoxic T cells, inverse CD4:CD8 ratio, significantly elevated pro-inflammatory cytokines, and subsequent clearance of the poliovirus suggests a possible link between inflammatory diarrheal illness and clearance of iVDPV. Our findings suggest that in the absence of B cells and sufficiently activated T/NK cells, macrophages and other T cells may produce auto-inflammatory conditions by TLR/RLR ligands expressed by previous/ongoing bacterial or viral infections to clear VDPV infection. The study highlights the need to screen all the patients with combined immunodeficiency for poliovirus excretion and intermittent follow-up of their immune parameters if found positive, in order to manage the risk of iVDPV excretion in the polio eradication endgame strategy.

1 May 2021 in Indian Journal of Medical Research
Verified
Journal Article
Open access
MMMadhu Chhanda Mohanty
Madhu Chhanda Mohanty
SVSwapnil Yashwant Varose
Swapnil Yashwant Varose
USUnnati Prashant Sawant
Unnati Prashant Sawant
MFMevis Minin Fernandes
Mevis Minin Fernandes
Background & objectives: Upper respiratory mucosa is the entryway for SARS-CoV-2, and cells at this site form the first line of resistance against the pathogens. Innate immune response at this point is crucial for managing the replication and early stage symptoms of virus infection. This study was aimed to evaluate the expression of pattern recognition receptors and cytokines in upper airway cells of SARS-CoV-2 infected patients. Methods: Forty seven nasopharyngeal swab (NPS) specimens from 25 SARS-CoV-2 infected patients and 22 SARS-CoV-2 negative individuals were investigated for expression of toll-like receptors (TLRs), melanoma differentiation-associated protein 5 (MDA5), NOD-like receptors family pyrin domain containing 3 (NLRP3), angiotensin-converting enzyme 2 (ACE2), interleukin (IL) - 6, tumour necrosis factor alpha (TNFα) and type-1 interferons (IFNs) by real time reverse transcription polymerase chain reaction. Results: Increased expression of TLR2, MDA5 and ACE2 was detected in SARS-CoV-2 infected patients in comparison with controls. MDA5 expression was significantly higher in asymptomatic and mildly symptomatic SARS-CoV-2 positive patients than the patients with severe symptoms. The asymptomatic group showed significant induction of type 1 IFNs than the symptomatic group. Non-specific induction of TLR7 could be observed in nasopharyngeal (NP) cells irrespective of symptoms and SARS-CoV-2 positivity. Interpretation & conclusions: The findings suggest that increased MDA5 in NP cells of asymptomatic SARS-CoV-2 positive patients may subsequently induce type 1 IFNs to protect the individuals from further clinical severity of SARS-CoV-2 infection. A future prospective study in NPS of larger cohort needs to be performed to confirm our findings.

30 October 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MMMadhu Chhanda Mohanty
Madhu Chhanda Mohanty
KJKetki S. Jawade
Ketki S. Jawade
SRSushmita S. Rane
Sushmita S. Rane
ADAmeet Dravid
Ameet Dravid
YGYogesh K. Gurav
Yogesh K. Gurav
PAPriya Abraham
Priya Abraham
Post-Acute Sequelae of COVID-19 or Long COVID (LC) affects millions globally, with persistent immune, neurological, and cardiovascular symptoms posing challenges to healthcare. This study analyses clinical, demographic, and lifestyle differences between LC and recovered (RC) individuals residing in Western India, extending observations up to four years post-infection. A cross-sectional study was conducted in four urban setting tertiary-care hospitals of Western India. Individuals aged 19-70 with documented SARS-CoV-2 infection and persistent or fluctuating symptoms beyond four weeks, unexplained by other diagnoses were recruited in LC group. Recovered individuals with confirmed past infection, negative SARS-CoV-2 RT-PCR at the time of enrolment, and no lingering symptoms were recruited in RC group. The demographic, socio-economic, and clinical data were collected. Severe acute COVID-19 patients were more frequent in the LC group (n = 104) compared to the RC group (n = 83), though both LC and RC had similar proportions of mild/moderate acute COVID-19 patients. Fatigue was the most persistent symptom (79.80 %), followed by cough and anxiety. Respiratory, cardiovascular, neuro-psychiatric symptoms declined over time, while dermatological, ENT, gastrointestinal, and muscular symptoms fluctuated. LC patients predominantly had hypertension as comorbidity, lower SPO2, and higher pulse rates (p < 0.0001). Rates of hospitalization for COVID-19 treatment were similar, but mechanical ventilation use was exclusively observed in LC patients (10.6 %). Sedentary lifestyles were more frequent in LC (17.30 %) vs. RC (6.02 %, p = 0.0248). Our study is one of the few in Indian population showing occurrence of multiple LC symptoms after 3-4 years of infection. We report severity of COVID-19, use of Remdesivir and mechanical ventilation to be associated with increased odds of LC. Fatigue, cough and anxiety were the most common symptoms reported by LC participants. Our findings establish a much-needed baseline for understanding symptom progression in LC patients, emphasizing the need for targeted interventions and long-term monitoring.

6 July 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
MMMadhu Chhanda Mohanty
Madhu Chhanda Mohanty
MDMukesh Desai
Mukesh Desai
AMAhmad Mohammad
Ahmad Mohammad
AAAmita Aggarwal
Amita Aggarwal
GGGeeta Madathil Govindaraj
Geeta Madathil Govindaraj
MMManisha Madkaikar
Manisha Madkaikar
The emergence of vaccine-derived polioviruses (VDPVs) in patients with Primary Immunodeficiency (PID) is a threat to the polio-eradication program. In a first of its kind pilot study for successful screening and identification of VDPV excretion among patients with PID in India, enteroviruses were assessed in stool specimens of 154 PID patients across India in a period of two years. A total of 21.42% of patients were tested positive for enteroviruses, 2.59% tested positive for polioviruses (PV), whereas 18.83% of patients were positive for non-polio enteroviruses (NPEV). A male child of 3 years and 6 months of age diagnosed with Hyper IgM syndrome was detected positive for type1 VDPV (iVDPV1) with 1.6% nucleotide divergence from the parent Sabin strain. E21 (19.4%), E14 (9%), E11 (9%), E16 (7.5%), and CVA2 (7.5%) were the five most frequently observed NPEV types in PID patients. Patients with combined immunodeficiency were at a higher risk for enterovirus infection as compared to antibody deficiency. The high susceptibility of PID patients to enterovirus infection emphasizes the need for enhanced surveillance of these patients until the use of OPV is stopped. The expansion of PID surveillance and integration with a national program will facilitate early detection and follow-up of iVDPV excretion to mitigate the risk for iVDPV spread.